Arrowhead Pharma purchases land ahead of new manufacturing facility buildout
New campus will support the company as it approaches potential commercialisation of its rapidly progressing clinical candidates
Arrowhead Pharmaceuticals, a company specialising in harnessing RNAi technology to silence disease-causing genes, has purchased 13 acres of land in the Verona Technology Park in Verona, WI with a view to building a new 140,000-sq. ft GMP manufacturing plant.
The company also plans to build an associated laboratory and office facility, occupying approximately 115,000 sq. ft, to support process development and analytical activities.
The transaction comes at a time when, according to Arrowhead's president and CEO Christopher Anzalone, the company's investigational RNAi medicines continue to expand rapidly.
The new campus will, therefore, enable the company to advance the manufacturing process, including at commercial scale, of its TRiM-(Targeted RNAi Molecule) enabled drug candidates.
The company claims therapeutics developed with this platform offer several advantages, including simplified manufacturing and reduced costs, and multiple routes of administration.
Construction of the $200–250 million investment is expected to begin in the first quarter of 2022. Completion of the lab and office space is scheduled for the first quarter of 2023, andcompletion of the manufacturing facility is anticipated in the fourth quarter of 2023.
During this time, Arrowhead will continue to operate additional R&D facilities in Madison, WI, and San Diego, CA.
Once complete, the new facility is set to create about 250 new local jobs.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.